Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kosei Taniguchi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
IJU Case Reports|February 23, 2026
A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and PembrolizumabKosei Taniguchi, Mamoru Hashimoto, Takahito Nakayama, et al.
In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
IJU Case Reports|February 23, 2026
A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and PembrolizumabKosei Taniguchi, Mamoru Hashimoto, Takahito Nakayama, et al.
In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
Pageof 1